Bocidelpar

Bocidelpar or ASP0367 or MA-0211 is an experimental drug that may improve mitochondria and endothelial function. Bocidelpar is undergoing clinical trials under the name ASP0367 for Duchenne Muscular Dystrophy, ME/CFS and a number of other diseases mitochondria involving mitochondria dysfunction.

Evidence
The first clinical trial for ME/CFS is trial NCT04855201, which has not yet published any results. The trial involves 40 adults aged between 18 and 60, and is randomized clinical trial with quadruple blinding.

Clinicians
David Systrom is helping conduct the current clinical trial of bocidelpar at Brigham and Women's Hospital, Boston, United States.

Risks and safety
Unknown.

Learn more

 * ASP0367 (MA-0211) development pipeline
 * April 2022, $8 Million Clinical Trial of a Mitochondrial Booster Underway in ME/CFS - Cort Johnson, Health Rising